Educational content only. Not medical advice. The content creators are not doctors or medical professionals. Consult your healthcare provider before taking any action.
Quick answer
CJC-1295 and ipamorelin are both growth-hormone-releasing peptides that act on different receptors — CJC-1295 is a GHRH analog (amplifies the GH signal), ipamorelin is a selective ghrelin-receptor agonist (triggers a GH pulse). They're complementary, not competitors. Neither is FDA-approved.
CJC-1295 and ipamorelin are both growth-hormone-releasing peptides, but they work through different receptors: CJC-1295 is a GHRH analog, while ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. They are studied together because their mechanisms are complementary. Neither is FDA-approved, and human data remain limited. This guide compares mechanism, dosing parameters, half-life, side effects, and legal status.
CJC-1295 vs ipamorelin at a glance
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Class | GHRH analog (modified GRF 1-29) | Selective GH secretagogue (pentapeptide, ghrelin mimetic) |
| Receptor | GHRH receptor on pituitary somatotrophs | Growth hormone secretagogue receptor (GHS-R1a / ghrelin receptor) |
| Action | Increases the amount of GH released per pulse and raises trough/baseline GH | Triggers a pulse of GH release; amplifies pulse |
| Commonly cited dose (research context) | "With DAC": ~30–60 mcg/kg in human trials. "No-DAC" (mod GRF 1-29): research protocols often cite ~100 mcg | Research protocols commonly cite ~100–300 mcg per dose |
| Half-life | With DAC: ~5.8–8.1 days (Teichman 2006). No-DAC: ~30 minutes | ~2 hours (commonly cited; [VERIFY: exact human half-life]) |
| Effect on cortisol / prolactin | Minimal (GHRH-pathway) | Minimal — notably selective; little ACTH/cortisol/prolactin change (Raun 1998) |
| Appetite stimulation | Negligible | Low relative to GHRP-6 (ghrelin mimetic, but more selective) |
| FDA status (2026) | Not approved; not on the 503A bulks list (gray area) | Not approved; not on the 503A bulks list (gray area) |
What is the core difference between CJC-1295 and ipamorelin?
CJC-1295 and ipamorelin both aim to raise the body's own growth hormone (GH) output, but they pull different levers in the GH axis.
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). Its backbone is a modified version of the first 29 amino acids of human GHRH (often called "modified GRF 1-29"), with substitutions at positions 2, 8, 15, and 27 that resist enzymatic breakdown — most importantly blocking cleavage by the DPP-IV enzyme at position 2 (Particle Peptides regulatory summary; Wikipedia/peer-reviewed structural data). CJC-1295 binds GHRH receptors on the somatotroph cells of the anterior pituitary, prompting those cells to synthesize and release more GH. In effect, it tells the pituitary to make a bigger GH signal.
Ipamorelin takes a completely different path. It is a synthetic pentapeptide (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) that mimics the stomach hormone ghrelin. It binds the growth hormone secretagogue receptor type 1a (GHS-R1a) — the ghrelin receptor — and triggers a discrete pulse of GH release (Raun et al., 1998, European Journal of Endocrinology). Where CJC-1295 enriches the signal, ipamorelin pulls the trigger.
Because GHRH receptors and ghrelin receptors are separate systems, the two compounds are frequently studied as a pair: a GHRH analog plus a GHRP-class secretagogue can produce a larger combined GH response than either pathway alone (Bowers et al., 1990, J Clin Endocrinol Metab). That synergy — not a head-to-head superiority of one molecule — is the real reason "CJC-1295 vs ipamorelin" is so often discussed as "CJC-1295 and ipamorelin." For deeper background, see our growth hormone peptides hub.
How does CJC-1295 work?
CJC-1295 works by amplifying the GHRH side of the growth-hormone axis. Under normal physiology, the hypothalamus releases GHRH in pulses; GHRH then binds receptors on pituitary somatotrophs, which release GH. CJC-1295 is engineered to imitate GHRH while lasting far longer in circulation.
There are two distinct forms, and conflating them is the most common error in CJC-1295 discussions:
- CJC-1295 with DAC carries a "Drug Affinity Complex" — a chemical group that bonds covalently to circulating albumin after injection, dramatically extending its life in the body. In the foundational human trial, the estimated half-life was 5.8–8.1 days (Teichman et al., 2006, J Clin Endocrinol Metab). A single subcutaneous injection produced dose-dependent increases in mean plasma GH of 2- to 10-fold for 6 days or more, and increases in IGF-1 of 1.5- to 3-fold for 9–11 days; with repeated dosing, mean IGF-1 stayed above baseline for up to 28 days, with no serious adverse reactions reported (Teichman et al., 2006).
- CJC-1295 without DAC (modified GRF 1-29) lacks the albumin-binding moiety and has a much shorter half-life — commonly cited at roughly 30 minutes (Particle Peptides regulatory/PK summary). This short window is why the no-DAC form is typically paired with a fast-acting secretagogue like ipamorelin: the brief GHRH "primer" overlaps with the secretagogue's pulse.
A key finding for the DAC form is that continuous GHRH stimulation does not flatten the natural pulsatile pattern of GH. In healthy men, one week after a single 60 or 90 mcg/kg injection, basal GH rose roughly 7.5-fold, mean GH rose about 46%, and IGF-1 rose about 45%, while GH pulse frequency and amplitude were preserved (Ionescu & Frohman, 2006, J Clin Endocrinol Metab). Preserved pulsatility matters because non-pulsatile, continuously high GH is associated with less favorable signaling.
Research protocols in the literature commonly cite human doses of 30 or 60 mcg/kg for the DAC form (Teichman et al., 2006), and around 100 mcg per dose for the no-DAC form in non-clinical use — but these are research-context figures, not a prescription. Dosing should be personalized with a provider. See the CJC-1295 protocol guide for a fuller breakdown. Consult your healthcare provider before starting any peptide protocol.
How does ipamorelin work?
Ipamorelin works on the ghrelin side of the GH axis. It binds GHS-R1a, the same receptor activated by ghrelin, and stimulates a pulse of GH release from the pituitary through calcium-dependent signaling cascades distinct from the cAMP pathway that GHRH analogs use (Ishida et al., 2020, JCSM Rapid Communications; Raun et al., 1998).
Ipamorelin's defining feature is selectivity. When researchers first characterized it, ipamorelin released GH with high potency and efficacy yet — unlike earlier secretagogues — did not meaningfully raise ACTH, cortisol, prolactin, FSH, LH, or TSH, even at doses far above the threshold needed for GH release (Raun et al., 1998, European Journal of Endocrinology). That is the contrast that gave ipamorelin its "first selective growth hormone secretagogue" label.
This matters when comparing ipamorelin to the older GHRP-class peptides. GHRP-6 and, to a lesser degree, GHRP-2 produce dose-dependent increases in cortisol and prolactin and stronger appetite stimulation through their ghrelin-mimetic activity (Sigalos & Pastuszak, 2017, Sexual Medicine Reviews; secretagogue comparative literature). Ipamorelin's cleaner profile is its main practical selling point within the secretagogue family — fewer off-target hormonal effects for a similar GH stimulus.
It is worth being precise about evidence quality: ipamorelin's selectivity is well characterized in animal models and early pharmacology, but it has never received FDA approval for any indication, and large long-term human efficacy and safety trials are lacking (Sigalos & Pastuszak, 2017). Research protocols commonly cite ipamorelin doses in the ~100–300 mcg range per administration, often timed before sleep or post-exercise to align with natural GH pulses, but these are not prescriptions. See the ipamorelin protocol guide. Consult your healthcare provider before starting any peptide protocol.
When should you consider CJC-1295 vs ipamorelin? (decision matrix)
There is no validated head-to-head human trial naming a "winner." The framing below reflects how the two mechanisms are described in the research literature — it is educational, not a recommendation to use either compound.
| Scenario / goal context | Mechanistic note | Commonly discussed framing |
|---|---|---|
| Interest in raising baseline/trough GH and IGF-1 over days | CJC-1295 with DAC has a multi-day half-life and sustained IGF-1 elevation (Teichman 2006) | CJC-1295 (DAC) is the long-acting GHRH lever |
| Interest in mimicking a natural GH pulse near sleep or training | Ipamorelin triggers a discrete pulse via the ghrelin receptor (Raun 1998) | Ipamorelin is the short-acting pulse lever |
| Concern about cortisol / prolactin / appetite side effects | Ipamorelin is the most selective secretagogue characterized (Raun 1998) | Ipamorelin over older GHRPs (GHRP-6/GHRP-2) |
| Interest in a larger combined GH response | GHRH + GHRP act synergistically (Bowers 1990) | The "CJC-1295 + ipamorelin" pairing |
| Preference for fewer injections | DAC form persists ~6–8 days (Teichman 2006) | CJC-1295 with DAC |
| Preference for tighter control / dosing flexibility | No-DAC CJC-1295 clears in ~30 minutes | Modified GRF 1-29 + ipamorelin |
The recurring theme: these peptides are usually framed as complementary, not as substitutes. A long-acting or short-acting GHRH analog supplies the amplified signal; ipamorelin supplies a clean pulse. Any decision about whether either is appropriate is a medical decision. Consult your healthcare provider before starting any peptide protocol.
What are the side effects of CJC-1295 vs ipamorelin?
Both compounds lack large long-term human safety datasets, so the side-effect picture is drawn from early trials, the broader growth-hormone-secretagogue literature, and known effects of elevating GH/IGF-1. Safety claims below are sourced; none should be read as reassurance that these peptides are safe for any individual.
| Side effect domain | CJC-1295 | Ipamorelin |
|---|---|---|
| Injection-site reactions | Reported (redness, itching) in human GHRH-analog trials (Teichman 2006) | Reported; generally mild in early studies |
| Water retention / edema | Possible via GH/IGF-1 elevation (GHS literature: Sigalos & Pastuszak, 2017) | Possible via the same mechanism |
| Glucose / insulin sensitivity | Elevated IGF-1 can reduce insulin sensitivity; hyperglycemia is the most consistent GHS safety signal (Sigalos & Pastuszak, 2017) | Same class-level concern |
| Cortisol / prolactin | Minimal — GHRH pathway does not strongly drive these | Minimal — ipamorelin is selective (Raun 1998), unlike GHRP-6 |
| Appetite | Negligible | Lower than GHRP-6; ghrelin-receptor activity can still affect hunger |
| Long-term malignancy / mortality | No long-term safety data available for GHSs (Sigalos & Pastuszak, 2017) | No long-term safety data available for GHSs (Sigalos & Pastuszak, 2017) |
The single most important class-level caveat is the one Sigalos and Pastuszak (2017) emphasize: GH secretagogues are generally "well tolerated" in short trials, but no safety data examining malignancy and mortality are currently available, and the consistent metabolic signal is increased blood glucose / decreased insulin sensitivity from elevated IGF-1. Because GH and IGF-1 are growth signals, anyone with a history of cancer, active malignancy, diabetes, or pituitary disease faces heightened theoretical risk and should not approach these compounds without medical supervision. Consult your healthcare provider before starting any peptide protocol.
Can you stack CJC-1295 and ipamorelin together?
In the research literature, CJC-1295 and ipamorelin are more often discussed as a combination than as competitors — and there is a clear mechanistic rationale for it.
GHRH analogs and ghrelin-receptor secretagogues act through separate receptors and separate intracellular pathways, so combining them can produce a GH response greater than the sum of each alone. This synergy is well established for the broader GHRH + GHRP class: in healthy men, submaximal GHRP plus GHRH stimulated GH release synergistically rather than merely additively (Bowers et al., 1990, J Clin Endocrinol Metab), and combined GHRH + GHRP administration consistently produces larger GH release than either compound alone (Determinants of GHRH/GHRP synergy, Am J Physiol Endocrinol Metab, 2009). Ipamorelin's selectivity is what makes it an attractive GHRP-class partner: it adds a pulse without the cortisol, prolactin, and intense-appetite baggage of GHRP-6 (Raun et al., 1998; Sigalos & Pastuszak, 2017).
Practically, this is why a short-acting GHRH primer (modified GRF 1-29 / no-DAC CJC-1295) is frequently paired with ipamorelin — the two windows overlap so the pituitary receives both an amplified signal and a trigger at the same moment. The DAC form, with its multi-day half-life, is sometimes paired with ipamorelin on a less frequent schedule.
None of this establishes that stacking is safe or effective in humans over time — the synergy data describe acute GH release, not long-term outcomes, body composition, or safety. Combining two non-approved compounds also compounds the unknowns. See our related comparisons, sermorelin vs CJC-1295 and tesamorelin vs ipamorelin, for how other GH-axis peptides fit in. Consult your healthcare provider before starting any peptide protocol.
What do CJC-1295 and ipamorelin cost, and are they legal? (2026)
Peptides.NYC does not sell peptides and does not facilitate purchase. This section is educational and current as of June 2026.
Regulatory status. Neither CJC-1295 nor ipamorelin is FDA-approved for any human indication. Their compounding status has been volatile:
- In September 2023, FDA placed CJC-1295 and ipamorelin acetate into Category 2 of the interim 503A bulk drug substances list — the "may present significant safety risks" bucket — effectively restricting compounding pharmacies from using them (FDA 503A bulk drug substances process; FDA Law Blog coverage).
- In September 2024, FDA removed CJC-1295 and ipamorelin from Category 2 after the original nominators withdrew their nominations — a procedural removal, not an endorsement (FDA Law Blog, 2026).
- The Pharmacy Compounding Advisory Committee (PCAC) voted against adding CJC-1295 and ipamorelin to the 503A bulks list at meetings in October and December 2024 (FDA Law Blog, 2026).
- At the July 23–24, 2026 PCAC meeting, the seven peptides under review are BPC-157, KPV, TB-500, MOTS-C, DSIP (emideltide), Semax, and Epitalon. CJC-1295 and ipamorelin are not on that agenda (FDA PCAC meeting notice, July 23–24, 2026; FDA Law Blog, 2026).
The net effect in 2026: CJC-1295 and ipamorelin sit in a regulatory gray area — not flagged in Category 2, but not on the 503A bulks list and not approved. Removal from Category 2 "does not, by itself, place these substances on the 503A bulks list or into Category 1" (Orrick regulatory summary, April 2026). Formal rulemaking would be required for any approved compounding pathway, a process that can take more than a year (FDA Law Blog, 2026).
Cost. Because these are not approved drugs, there is no consistent NYC clinical price. Figures circulating in wellness and gray-market channels vary widely and are not verifiable against any standardized source [VERIFY: any specific NYC dollar figure]. Products sold "for research use only" are not quality-controlled for human use, and purity/identity cannot be assumed.
Legal status varies by jurisdiction and is changing quickly; consult a lawyer for binding advice. Consult your healthcare provider before starting any peptide protocol.
Frequently asked questions
Q: What is the main difference between CJC-1295 and ipamorelin? A: CJC-1295 is a GHRH analog — it binds GHRH receptors on the pituitary and increases the amount of growth hormone released, while also raising baseline GH and IGF-1 over time. Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist that triggers a discrete pulse of GH release. They act on different receptors through different signaling pathways, which is why they are often studied as a complementary pair rather than as substitutes. Neither is FDA-approved. Discuss any GH-axis protocol with a healthcare provider.
Q: Is CJC-1295 or ipamorelin better for building muscle? A: No validated human head-to-head trial designates either as "better" for muscle. Both work indirectly by raising the body's own GH and IGF-1, and the research literature most often discusses them combined for a larger GH response (Bowers et al., 1990). Human data on body-composition outcomes for either peptide are limited, and neither is FDA-approved. Claims of guaranteed muscle gain are not supported by the evidence. See our muscle-growth peptides overview and consult your healthcare provider.
Q: What is the half-life of CJC-1295 vs ipamorelin? A: It depends on the CJC-1295 form. CJC-1295 with DAC has an estimated half-life of about 5.8–8.1 days because it binds to albumin (Teichman et al., 2006). CJC-1295 without DAC (modified GRF 1-29) clears in roughly 30 minutes. Ipamorelin's half-life is commonly cited at around two hours [VERIFY: exact human half-life]. These pharmacokinetic differences explain why the short-acting forms are typically paired together and the DAC form is dosed less often.
Q: Does ipamorelin raise cortisol like other peptides? A: Ipamorelin is notable for not meaningfully raising cortisol, ACTH, or prolactin even at doses well above its GH-releasing threshold — this selectivity is what earned it the description "first selective growth hormone secretagogue" (Raun et al., 1998). That distinguishes it from older GHRP-class peptides like GHRP-6, which can raise cortisol and prolactin and strongly stimulate appetite (Sigalos & Pastuszak, 2017). Individual responses still vary, and long-term human data are lacking. Consult your healthcare provider.
Q: Why are CJC-1295 and ipamorelin used together? A: They act on two separate receptors — the GHRH receptor and the ghrelin receptor — through different intracellular pathways, so combining them can produce a synergistic (greater-than-additive) GH response (Bowers et al., 1990). CJC-1295 amplifies the GH signal; ipamorelin adds a clean pulse without the cortisol and appetite effects of less selective secretagogues. Importantly, this synergy is documented for acute GH release, not for long-term safety or body-composition outcomes. Combining two non-approved compounds also multiplies the unknowns.
Q: Are CJC-1295 and ipamorelin legal in 2026? A: Neither is FDA-approved. As of June 2026, both were removed from the FDA's Category 2 "significant safety risks" list (after nominations were withdrawn in 2024), but neither is on the 503A bulks list and neither is on the July 2026 PCAC review agenda — leaving them in a regulatory gray area, not an approved one (FDA Law Blog, 2026; FDA PCAC notice). "Research use only" products are not quality-controlled for human use. Legal status varies by jurisdiction; consult a lawyer for binding advice.
Q: How long do CJC-1295 and ipamorelin take to show effects? A: In the foundational human CJC-1295 trial, IGF-1 rose within days of a single injection and stayed elevated for up to 9–11 days (longer with repeated dosing) (Teichman et al., 2006). Ipamorelin produces an acute GH pulse within minutes to hours of administration in pharmacology studies (Raun et al., 1998). However, what these short-term hormonal changes mean for real-world goals like body composition or recovery is not established in robust human trials. Individual response varies; discuss expectations with a healthcare provider.
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne J-P, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006;91(3):799–805. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth Hormone (GH)-Releasing Peptide Stimulates GH Release in Normal Men and Acts Synergistically with GH-Releasing Hormone. J Clin Endocrinol Metab. 1990;70(4):975–982. https://pubmed.ncbi.nlm.nih.gov/2108187/
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2017;6(1):45–53. https://pmc.ncbi.nlm.nih.gov/articles/PMC5632578/
- Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085–E1092. https://pmc.ncbi.nlm.nih.gov/articles/PMC2681313/
- Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25–37. https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9
- U.S. Food & Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- U.S. Food & Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- Hyman, Phelps & McNamara (FDA Law Blog). FDA's Pep(tide) Rally! What Compounders and Industry Need to Know. April 2026. https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/
Written By
Editorial team. We cite published research; we are not licensed clinicians and content is not medically reviewed.
Medical Disclaimer
The information on this website is for educational purposes only and is not medical advice. The content creators are not doctors or medical professionals. This content should not be used to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before starting any new supplement, medication, or health protocol. You assume all risks associated with using this information.